Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells
Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control
Our Science
Redefining CAR-T with a next-generation approach:
AI-powered multiplex gene editing to overcome the immunosuppressive tumor microenvironment (TME) and drive superior efficacy in solid tumors.
AI-Driven Design
Harnessing advanced machine learning to identify and optimize multiplex gene-editing combinations, enabling CAR-T cells to resist TME suppression and enhance durability in solid tumors.
Multiplex Gene Editing
Utilizing cutting-edge gene editing to simultaneously engineer multiple suppressive pathway knockouts, enhancing CAR-T function and persistence in highly immunosuppressive environments.
Allogeneic CAR-T
Our healthy donor-derived CAR-T cells are designed for off-the-shelf accessibility and optimized to withstand the harsh conditions of the solid tumor microenvironment, ensuring sustained potency and therapeutic impact.
Our Support
Our Recognitions
Nucleate Activator Program
Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston
Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston
Co-founder and CEO, Aaron Edwards selected to be a Termeer Fellow, a values-driven leadership program for first time biotech founder/CEOs
HUCP Innovation Fund x CBE Ventures Competition
HUCP Innovation Fund x CBE Ventures Competition
Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, the Environment Venture Competition
Finalists in the 2024 M2D2 $200k Grand Challenge
Presidents Innovation Challenge
Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge
Co-founder and CSO, Ryan Murray selected to be in 5050 Program, helping foster deep tech scientists/engineers become great founders.
